LABA+LAMA+ICS

Phase 3Small molecule

UUniversity of British Columbia

LABA+LAMA+ICS is one of 4 small molecule programs targeting Corticosteroids. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CorticosteroidsNot yet recruiting

CorticosteroidsPhase 3

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Corticosteroids

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Approved

7 2

Cytoxan

BBaxter Healthcare Corporation

Phase 3

1 3

Doxorubicin Hydrochloride Liposome

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

1 4

LABA+LAMA+ICS

UUniversity of British Columbia

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Post-ApprovalNot yet recruiting

Corticosteroids

NCT06552364

Clinical

Trials by Indication[1]

Corticosteroids1 trial

Air Pollution and Inhaled Corticosteroids in COPD

Not yet recruiting·UUniversity of British Columbia·Phase 4·NCT06552364·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LABA+LAMA+ICS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LABA+LAMA+ICS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LABA+LAMA+ICS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of British Columbia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of British Columbia

LABA+LAMA+ICS

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Corticosteroids1 trial

References

Drug Info

Quick Facts

Related News